Bilag 5. AMSTAR og Risk of Bias Tool.

reported.

A. AMSTAR: Måleredskab til vurdering af systematiske reviews.

| 1. Was an 'a priori' design provided? | □ Yes |
|--|--|
| The research question and inclusion criteria should be established before the conduct of the review. | □ No □ Can't answer □ Not applicable |
| 2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. 3. Was a comprehensive literature search performed? | ☐ Yes ☐ No ☐ Can't answer ☐ Not applicable ☐ Yes |
| At least two electronic sources should be searched. The report must include years and databases used (e.g. Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. | ☐ No ☐ Can't answer ☐ Not applicable |
| 4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. | ☐ Yes ☐ No ☐ Can't answer ☐ Not applicable |
| 5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. | ☐ Yes ☐ No ☐ Can't answer ☐ Not applicable |
| 6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g. age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be | ☐ Yes ☐ No ☐ Can't answer ☐ Not applicable |

| 7. Was the scientific quality of the included studies assessed and documented? `A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. | ☐ Yes ☐ No ☐ Can't answer ☐ Not applicable |
|---|--|
| 8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. | ☐ Yes ☐ No ☐ Can't answer ☐ Not applicable |
| 9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e. Chi-squared test for homogeneity, I²). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e. is it sensible to combine?). | ☐ Yes ☐ No ☐ Can't answer ☐ Not applicable |
| 10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test). | ☐ Yes ☐ No ☐ Can't answer ☐ Not applicable |
| 11. Was the conflict of interest stated? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. | □ Yes □ No □ Can't answer □ Not applicable |

B. The Cochrane Collaboration's tool for assessing risk of bias in RCT

| Domain | | Description | | | Review authors' judgement | |
|--|---|--|---|--|---|--|
| Sequence generation | | Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. | | | Was the allocation sequence adequately generated? | |
| Allocation concealment | | Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen in advance of, or during, enrolment. | | | Was allocation adequately concealed? | |
| Blinding of participants, personnel and outcome assessors Assessments should be made for each main outcome (or class of outcomes) | | Describe all measures used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective. | | | Was knowledge of the allocated intervention adequately prevented during the study? | |
| Incomplete outcome data Assessments should be made for each main outcome (or class of outcomes) | | Describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. State whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomized participants), reasons for attrition/exclusions where reported, and any re-inclusions in analyses performed by the review authors. | | | Were incomplete outcome data adequately addressed? | |
| | | State how the possibility of selective outcome reporting was examined by the review authors, and what was found. | | | Are reports of the study free of suggestion of selective outcome reporting? | |
| Other sources of bias | | State any important concerns about bias not addressed in the other domains in the tool. If particular questions/entries were pre-specified in the review's protocol, responses should be provided for each question/entry. | | | Was the study apparently free of other problems that could put it at a high risk of bias? | |
| Risk of bias | Interpretation | ····· - ···· ···· ···· ···· | Within a study | Across stu | Across studies | |
| Low risk of bias | Plausible bias unlikely to seriously alter the results. | | Low risk of bias for all key domains. | Most information is from studies at low risk of bias. | | |
| Unclear risk of bias | Plausible bias that raises some doubt about the results | | Unclear risk of bias for one or more key domains. | Most information is from studies at low or unclear risk of bias. | | |
| High risk of bias | Plausible bias t confidence in th | hat seriously weakens ne results. | High risk of bias for one or more key domains. | The proportion of information from studies at high risk of bias is sufficient to affect the interpretation of the results. | | |